Literature DB >> 12964080

[Contrast-enhanced MR angiography of the arterial and portovenous system of the liver with varying concentrations of contrast medium].

R Vosshenrich1, B Engeroff, S Obenauer, E Grabbe.   

Abstract

PURPOSE: To evaluate the diagnostic value of a higher concentrated contrast medium (gadobutrol) for contrast-enhanced MRA of the hepatic arteries and portovenous system.
MATERIALS AND METHODS: The examinations were performed on a 1.5-Tesla whole body imaging system (Magnetom Symphony Quantum, Siemens) with a 30-mTesla/m gradient field strength using a phased-array body coil. A 3D FLASH sequence (TR/TE/FA 3.88 ms/1.44 ms/25(3)) was used imaging the hepatic arteries and portovenous system after determination of the circulation time. The study included 50 patients, with 25 patients (group 1) injected with 0.2 mmol Gd-GTPA/kg body weight and 25 patients (group 2) injected with 0.1 mmol gadobutrol/kg body weight. The signal-to-noise ratio (SNR) and the contrast-to-noise ratio (CNR) were calculated for both groups. The image quality was graded by three radiologists on a 5-point scale.
RESULTS: The highest SNR was measured in group 1, with no statistically significant differences of the SNR in the abdominal aortal, coeliac trunk and common hepatic artery. CNR was also similar in both groups. Likewise, portal, superior mesenteric and splenic veins showed no statistically significant differences. All cases were found to have a good image quality.
CONCLUSION: For MRA of the hepatic arteries and the portal veins, the higher concentrated Gd-DTPA contrast medium gadobutrol can be used at half the dosage recommended for the standard Gd-DTPA contrast medium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964080     DOI: 10.1055/s-2003-41929

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  4 in total

1.  Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read.

Authors:  Werner Pennekamp; Daniela Roggenland; Steffen Hering; Stefan Lemburg; Soeren Peters; Sabrina Sterl; Carsten Schwenke; Volkmar Nicolas
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

2.  Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.

Authors:  M Koenig; G Schulte-Altedorneburg; M Piontek; A Hentsch; P Spangenberg; C Schwenke; A Harders; L Heuser
Journal:  Eur Radiol       Date:  2013-07-04       Impact factor: 5.315

Review 3.  [Contrast agents in MRT. Substance, effects, pharmacology and validity].

Authors:  P Reimer; R Vosshenrich
Journal:  Radiologe       Date:  2004-03       Impact factor: 0.635

4.  Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial.

Authors:  Bernd Tombach; Klaus Bohndorf; Wolfgang Brodtrager; Claus D Claussen; Christoph Düber; Michael Galanski; Eckhardt Grabbe; Giacomo Gortenuti; Michael Kuhn; Walter Gross-Fengels; Renate Hammerstingl; Brigitte Happel; Gertraud Heinz-Peer; Gregor Jung; Thomas Kittner; Roberto Lagalla; Philipp Lengsfeld; Reinhard Loose; Raymond H G Oyen; Pietro Pavlica; Christiane Pering; Roberto Pozzi-Mucelli; Thorsten Persigehl; Peter Reimer; Nomdo S Renken; Götz M Richter; Ernst J Rummeny; Fritz Schäfer; Malgorzata Szczerbo-Trojanowska; Andrzej Urbanik; Thomas J Vogl; Paul Hajek
Journal:  Eur Radiol       Date:  2008-07-08       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.